Clinical Development RiskOutcomes in larger, controlled trials may differ from early-stage findings, which could jeopardize planned development milestones.
Need For Additional Funding And Dilution RiskCompletion of pivotal trials could require further capital, potentially resulting in shareholder dilution if new financing is necessary.
Regulatory Approval UncertaintyRegulatory authorities may require additional evidence or larger studies for approval, creating uncertainty around approval requirements.